Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O75508

UPID:
CLD11_HUMAN

ALTERNATIVE NAMES:
Oligodendrocyte-specific protein

ALTERNATIVE UPACC:
O75508; B2R7C1; D3DNQ5; Q5U0P3

BACKGROUND:
The protein Claudin-11, with its alternative name Oligodendrocyte-specific protein, plays a major role in the obliteration of the intercellular space through tight junction-specific cell-adhesion activity. This function is essential for the proper organization and maintenance of cellular barriers.

THERAPEUTIC SIGNIFICANCE:
Mutations in Claudin-11 are associated with the development of Leukodystrophy, hypomyelinating, 22, characterized by a spectrum of neurological impairments. The exploration of Claudin-11's function and its pathways offers a promising avenue for the development of novel therapeutic interventions for leukodystrophies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.